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ABSTRACT 
PATIENT SEX AND PHYSICIAN ADHERENCE TO TREATMENT GUIDELINES 
FOR NON-PURULENT CELLULITIS 
MAY 2019 
REBECCA F. GOLDBERG, B.S., UNIVERSITY OF MASSACHUSETTS, AMHERST, 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed by: Dr. Brian Whitcomb 
In 2015, participating US Emergency Departments (EDs) reported approximately 2.8 
million visits related to skin and soft tissue infections (SSTIs). Studies indicate that there 
may be disparities by patient sex in physician treatment guideline adherence rates as a 
result of a gender bias during physician-patient interactions; however, only two 
epidemiologic studies have investigated the role of patient sex in guideline adherence 
rates for SSTIs. These prior studies were limited in size and covariate assessment. Thus, 
the magnitude and direction of the effect of patient sex is uncertain, warranting further 
research. Therefore, we conducted a large prospective study to elucidate the role that 
patient sex plays in guideline adherence rates among physicians for non-purulent 
cellulitis at two UMass Memorial Health Care Group EDs in 2017. Data on treatment and 
sex was abstracted from electronic medical records. Compliance with treatment 
guidelines was based on 2014 Infectious Disease Society of America (IDSA) guidelines. 
Adjusted multinomial regressions indicated that female patient sex was associated with 
lower prevalence of overtreatment (POR=0.72, 95%CI: 0.57-0.92). In contrast, female 
physician sex was significantly associated with higher prevalence of overtreatment 
(POR=1.48, 95%CI: 1.16-1.87), but did not affect the relationship of patient sex with 
	 iv 
overtreatment (P-interaction=0.80). Awareness of differential treatment by patient sex 
may improve physician adherence to guidelines. This study contributes to a growing 
body of literature elucidating the role of sex in medical decision making and is the first to 
account for both patient and physician sex as well as relevant covariates in studies 
regarding cellulitis treatment. 
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CHAPTER I 
INTRODUCTION 
Non-purulent cellulitis is a common type of skin and soft tissue infection (SSTI) 
that is characterized by redness, warmth, and tenderness.1
 
In 2015, the National Hospital 
Ambulatory Medical Care Survey, including data from 267 United States (US) 
Emergency Departments (EDs), reported approximately 2.8 million visits related to 
cellulitis and abscess.2 Among females ages 15-64, 1.007 million visits to the ED were 
made for cellulitis and abscess as compared to 1.049 million visits among males.3
 
Studies 
have indicated that treatment adherence rates for SSTIs are about 40%.4,5
 
 
Cellulitis can resolve quickly if treated with antibiotics early, but if left untreated, 
treated late, or treated with the incorrect antibiotics, the infection can spread and in rare 
cases become fatal.3
 
Inappropriate treatment, or treatment that does not adhere to 
guidelines, can lead to the overuse of antibiotics and the development of bacterial 
resistance.4
 
Overuse of stronger antibiotics can result in antibiotic resistance or negative 
side effects, while prescription of antibiotics that are too weak may not treat the 
infection.6 The treatment course for cellulitis is determined by the Infectious Disease 
Society of America (IDSA)6
 
which denotes guidelines that rank infections as mild, 
moderate, and severe, with corresponding treatment protocols. These criteria use 
objective signs and symptoms such as systemic signs of infection, evidence of MRSA, 
IVDU, history of infection, or treatment for malignancy to make treatment decisions.6 
The protocols emphasize the importance of timely assessment and antibiotic 
administration.6  
The risk factors for physicians failing to adhere to treatment guidelines include 
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patient age4; a lack of awareness of specific guideline-recommendations7; tension 
between adhering to guidelines and the desire to individualize patient care7; physician 
skepticism of certain guideline- recommendations7; patient comorbidities5; need for 
antibiotic administration4,5; purulence (which requires alternative treatment protocols)5,6; 
and sex.4,5
 
Sex and race are known risk factors for treatment disparities for other diseases, 
such as acute coronary syndromes8
 
or Non-Hodgkin’s Lymphoma.9
 
Therefore, we 
evaluated the relationship between patient sex and physician guideline adherence for 
cellulitis. Physician sex can contribute to differences in physician-patient interactions 
through a gender bias during doctor-patient interactions.10,11
 
Three psychological 
mechanisms have been proposed to explain this bias: 1) gender stereotypes, 2) gender 
concordant or discordant pairings, and 3) approachability.10 Physicians may apply their 
own biases regarding certain patient sexes to treatment protocols, which could impact 
guideline adherence, despite objective measures of the infection. In addition, patients 
who feel less comfortable with their physician may provide less information (e.g. medical 
history) during visits. These poor interactions could translate to worse care and thus a 
lack of guideline adherence among physicians. 
Eight studies in the United States from the past five years have evaluated the 
association between patient sex and treatment guideline adherence among physicians for 
a variety of diseases4,5,12-16
 
or antibiotic administration,17
 
a core tenet of infection 
treatment guidelines.6
 
Only two studies evaluated treatment guideline adherence for skin 
and soft tissue infections, including cellulitis.4,5
 
Most of these studies, regardless of 
exposure and disease, demonstrate a significant difference in guideline adherence 
depending on patient sex.4,5,13,15-17 Two prior studies published in recent years examined 
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the specific relationship between patient sex and guideline adherence for non-purulent 
cellulitis,4,5
 
but these were limited in sample size, included purulent cases, and did not 
adjust for covariates.  
This study will adjust for known risk factors, such as age, and other potential 
confounders including race, comorbidities, and IVDU in the analysis. There is conflicting 
information regarding the direction of the SSTI treatment disparity between male and 
female patient.4,5 Despite this discrepancy, the overall literature indicates a negative 
association between female patient sex and physician guideline adherence. This study 
will be significant because it will contribute to a growing body of literature elucidating 
the role of sex in medical decision making, and it will be the first, to our knowledge, to 
evaluate this association with a large sample size and multivariable adjustment in relation 
to non-purulent cellulitis treatment. 
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CHAPTER II 
METHODS 
 
A.  Study Design 
This study includes data from a parent study aimed at determining the 
effectiveness of a treatment algorithm intervention based on IDSA guidelines in 
improving physician adherence to guidelines. Physicians were provided educational 
materials and personalized data regarding prior adherence rates with the goal of 
improving physician adherence rates over time. The intervention was implemented in 
June 2017, so visits prior to this date were considered pre-intervention and those after 
were considered post-intervention. Data for both studies included records of patients that 
presented to two EDs belonging to the UMass Memorial Health Care Group (UMMHC) 
between January 1 and December 31, 2017. One of the selected EDs is an urban tertiary 
care teaching hospital and the other is a community site, both serving a diverse 
population in Worcester, MA. Eligible individuals consisted of those over 18 years old 
who were diagnosed with non-purulent cellulitis in the ED during the 2017 calendar year. 
Subjects were ascertained by searching for cellulitis diagnoses among all electronic 
medical records (EMRs). Exclusion criteria consisted of: 1) incision and drainage with 
expression of purulent material, 2) incomplete medical record or 3) a repeat visit within 
four weeks for treatment of the same SSTI. Individuals could be included multiple times 
for different SSTIs. A total of 1,360 individuals met the criteria for enrollment. Guideline 
adherence of prescribed treatment to standard guidelines was defined as compliance with 
treatment guidelines published by the 2014 Infectious Disease Society of America 
(IDSA).6   
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B.  Exposure Assessment 
EMRs provided information on participant sex. Sex is a dichotomous variable 
defined as either male or female. Sex was defined by patients while filling out 
demographic surveys for the hospital and was confirmed during ED visits by nurses. 
 
C.  Outcome Assessment 
EMRs were also consulted for description of infection and treatment course. 
Guideline adherence was assessed using diagnostic criteria defined by the 2014 
Infectious Disease Society of America.6 To determine if treatment outcome was correctly 
assigned, two physicians assigned scores and compared them for agreement. If there was 
a discrepancy, a third physician was consulted to make an evaluation. Following the 
IDSA guidelines, patients were assigned a severity score for their non-purulent SSTI 
infection at the following levels: mild, moderate, or severe.6 These protocols involve 
different classes of antibiotics depending on the severity.6 Based on this classification, an 
anticipated treatment course was determined using corresponding treatment protocols 
from the IDSA for mild, moderate, and severe cases.6 The observed antibiotic course was 
similarly classified using these same levels. Finally, the anticipated and observed 
antibiotic courses were compared. A three-level outcome variable was created as follows: 
those with higher anticipated than observed antibiotic courses were considered 
undertreated; those with lower anticipated than observed were considered overtreated; 
and those with scores that matched were considered adherent. A two-level outcome 
classification was also assigned to reflect whether treatment was adherent to guidelines or 
not adherent (including undertreated and overtreated). Though variables collected from 
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EMRs regarding inpatient or ED care, such as treatment course, are more complex than 
those from outpatient care, and are more susceptible to inaccuracies,18 this multiple-
physician review system of EMRs was conducted to maximize the validity of this 
assessment.  
 
D.  Covariate Assessment 
Covariates were selected a priori due to demonstrated relationships in the 
literature. Data for these covariates were gathered from EMRs. These include age,4 
IVDU,5 race,8 and Charlson Comorbidity Index (CCI), a scale that predicts mortality 
given medical history.4 Medical history was captured from the EMR by trained research 
assistants and used to calculate CCI. CCI Score was converted into a categorical variable 
(Mild: ≤2, Moderate: 3-4, Severe: 5+) as established by the Index literature.19 Physician 
sex was also taken from the EMR using the name of the prescribing physician. If no 
prescribing physician was included in the EMR, the attending physician was used to 
classify physician sex. 
 
E.  Statistical Analysis 
 Bivariate analyses cross-tabulated both sex and covariates with treatment 
adherence level. Covariates include age category, CCI Score, race/ethnicity, history of 
IVDU, and physician sex. All covariates are categorical variables, and therefore were 
analyzed using chi-square tests, or Fisher’s exact test, given small sample sizes, with p-
values reported. Two-sided p-values ≤ 0.05 were considered statistically significant. 
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 The association between sex and both the two-level and three-level treatment 
guideline adherence outcomes were modeled using binomial and multinomial logistic 
regression with odds ratios and 95% CI’s reported. Covariates selected a priori were 
considered for inclusion in multivariable models. Any covariate that was significantly 
associated with the outcome at the 0.10 level was retained; similarly, if inclusion of a 
covariate resulted in a change of at least 15% to the coefficient estimate for the primary 
exposure (i.e., patient sex or physician sex), it was retained in the model.   
 The association of prescribing physician sex with guideline adherence was also 
investigated in a series of analyses. The association between physician sex and the three-
level outcome was assessed using a multinomial model and adjusted for covariates, as 
previously described. In order to evaluate both patient sex and physician sex with regard 
to guideline adherence, both physician and patient sex were then included in one model 
adjusting for each other. Admittance and IV drug administration were also analyzed as 
representations of more aggressive treatment methods that may have been differential by 
sex. To account for differences in adherence as a result of an intervention related to a 
different study outcome, the adjusted multinomial analyses of both physician and patient 
sex were stratified by intervention status. Finally, in order to evaluate physician sex as a 
modifier of the association of patient sex with physician guideline adherence, a 
multiplicative interaction term was included in models as physician sex*patient sex, and 
tested for statistical significance. Similarly, modification of associations of both patient 
sex and physician sex with outcomes by the trial intervention were considered; these 
were evaluated by inclusion of multiplicative interaction terms, patient sex*intervention 
status and physician sex*intervention status, and tested for statistical significance. 
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CHAPTER III 
RESULTS 
A.  Study Population Characteristics 
The original study population consisted of 1,524 patients diagnosed with a non-
purulent SSTI at one of the two ED sites (Table 1). Of this group, 36 were removed due 
to a documented incision and drainage for an abscess and 128 were repeat visits. The 
final study sample included 1,360 patients (Table 1). Minimal data was captured to 
characterize physicians. 
The patient population was 53.9% male with an average age of 50.82 (standard 
deviation (SD) = 18.16) (Table 2). The majority of patients was White (75.6%) and seen 
at the University campus (54.3%). Individuals were most likely to be discharged after 
treatment (69.3%), with fewer admitted (28.5%) or sent to the Clinical Decision Unit 
(CDU) (2.2%). Fevers occurred in 17% of patients, and the majority of patients had a 
mild CCI Score (Table 2). 
 
B.  Patient Sex and Physician Adherence 
Bivariate analysis of patient sex and treatment adherence type demonstrated a 
significant association (p=0.01). The largest percentage of males were overtreated 
(45.43%) while the largest percentage of females were appropriately treated (51.04%). 
An analysis of two-level treatment adherence demonstrated that female patient sex is 
associated with lower odds of physicians failing to adhere to guidelines after adjusting for 
CCI Score, race, and IVDU (POR = 0.75, 95%CI: 0.61-0.94) (Table 3). Other treatment 
outcomes such as disposition or IV antibiotic administration were not significantly 
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associated with sex (data not shown). Given these results, the three-level outcome and 
multinomial regression were used to differentiate between those over- and undertreated. 
Chi square analysis of the three-level outcome indicated that patient sex was a significant 
predictor of treatment adherence (p=0.01) (Table 4). In the multinomial regression 
adjusted for age over 65, CCI Score, race and IVDU, the protective effect was slightly 
attenuated though still significant among overtreated female patients (POR=0.72. 95%CI: 
0.57-0.91), but not statistically significant among undertreated (POR=0.89, 95%CI: 0.61-
1.29) (Table 4). Among male patients, 45% were overtreated, which is 7% higher than 
the percent of women who were overtreated.  
 
C.  Patient Sex and Physician Adherence, Stratified by Intervention Status 
An adjusted multinomial model of patient sex and treatment adherence was also 
stratified by intervention status in order to compare the association between the two time 
periods (Table 5). Comparing physician treatment adherence in female patients to that in 
male patients, similar results were observed regarding overtreatment for pre- (POR=0.77, 
95%CI: 0.55-1.08) and post-intervention (POR=0.67, 95%CI: 0.48-0.93). Point estimates 
for undertreatment varied between pre- and post-intervention, but results from adjusted 
models were not statistically significant for pre- (POR=1.09, 95%CI: 0.61-1.94) or post-
intervention (POR=0.78, 95%CI: 0.48-1.29), and the test for interaction was non-
significant (P-interaction=0.5), supporting no significant difference in the relationship 
between pre- and post-intervention periods. 
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D.  Physician Sex and Physician Adherence, Stratified by Intervention 
To explore alternative explanations for these observations, additional sensitivity 
analyses were conducted. We first investigated the role that physician sex may have 
played as a confounder or effect modifier of the association between patient sex and 
physician adherence. We then explored whether the relationships observed for both 
patient sex and physician sex were modified by the parent study intervention. In a 
multinomial model adjusted for categorical age, CCI Score, race, and IVDU, female 
physician sex was significantly associated with higher prevalence of overtreatment 
(POR=1.48, 95%CI: 1.16-1.88), but not with undertreatment (Table 4). Analysis 
stratified on intervention status was conducted to evaluate the association of physician 
sex with adherence separately pre- and post-intervention. In this analysis, higher odds of 
overtreatment were observed in both the pre-intervention period (POR=1.79, 95%CI: 
1.26-2.55) and post-intervention period (POR=1.28, 95%CI: 0.91-1.79); based on a test 
of interaction, these estimates were not statistically significantly different (P-
interaction=0.4) (Table 5). Comparison of estimates from the pre- and post-intervention 
periods suggest that implementation of the intervention reduced female physician 
overtreatment so that physician sex was not a significant predictor of guideline adherence 
in the post-intervention group (p=0.34).  
 
E.  Patient Sex and Physician Sex Interaction 
Further analyses to test the role of physician sex were conducted in a model that 
included both patient sex and physician sex. To address the possibility that adherence 
might vary by combinations of physician and patient sex (e.g., concordant vs. discordant 
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pairings), models including an interaction term were evaluated. There was no significant 
interaction between physician sex and patient sex (P-interaction=0.80), suggesting that 
associations of patient sex with treatment adherence were similar regardless of physician 
sex (Figure 1). A multinomial model (adjusted for age category, CCI Score, race and 
IVDU) that includes physician sex without the interaction term indicated that female 
patient sex was significantly protective against overtreatment (POR=0.72, 95%CI: 0.57-
0.92), and female physician sex increased the odds of overtreatment (POR=1.47, 95%CI: 
1.16-1.87) (Table 4). 
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CHAPTER IV 
DISCUSSION 
 In this study, we observed that treatment guideline adherence varied by patient 
sex and physician sex. Analysis of the two-level adherence outcome demonstrated that 
female patients were more likely to be treated according to guidelines, which is consistent 
in direction with literature concerning SSTI treatment. One prior study by Ezebuenyi et 
al. reported that the odds of males being treated according to guidelines as compared to 
females was 0.495, or 50.5% reduced odds.5 The stronger association seen in this prior 
study could be attributed to the relatively small sample size, which also included many 
purulent cases.5 In fact, half of the sample size in the study consisted of purulent 
infections, which is independently related to both male sex and physician failure to 
adhere to treatment guidelines.4,5 Of note, the direction of association demonstrated in 
both our study and the prior by Ezebuenyi et al. is opposite to results shown in literature 
for other health issues.13,15,16,17 The cause of this disparity is unclear. 
The three-level analysis demonstrated that female patient sex was protective 
against overtreatment for cellulitis compared to male patient sex. This result also 
indicates that males received more aggressive treatments compared to females. Steps 
taken to adjust for possible confounders and effect modifiers did little to change these 
findings. This result is consistent with prior literature in this setting, although our 
findings did not replicate prior findings of increased risk of undertreatment.4  
Physician sex is also known to contribute to differences in physician-patient 
interactions,10,11 which could impact guideline adherence. The findings of this study 
indicated that female physician sex was associated with decreased odds of adherence to 
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guidelines. The association between physician sex and adherence is understudied in 
literature; thus, there is little evidence to support or contradict this finding. Prior literature 
has indicated that improved physician-patient relationships are associated with female 
physicians due to more thorough conversations and amiable actions, which could 
manifest as improved treatment and guideline adherence.10,11 Our analysis indicates that 
there was no interaction between patient and physician sex, although there is a lack of 
literature to compare this finding with regarding the role of interaction in adherence.  
This research indicates that differential care by sex remains an issue in healthcare, 
though interventions aimed at improving care are effective. As seen in this analysis, the 
parent study intervention reduced rates of over- and undertreatment, and uptake of the 
intervention was not significantly different among physician or patient sexes. These 
findings are significant because they identify more specific disparities in treatment, with 
implications for targeted interventions. 
This study is part of a larger one involving an intervention aimed at lowering rates 
of overtreatment, which contributed to the lowered measures of association seen among 
both physician and patient sex after stratification. Physicians, regardless of sex, may be 
much more conscious of overtreatment after the intervention, although changes in 
adherence after the intervention do not significantly differ by patient sex. In addition, 
stratifying the three-level outcome may have resulted in cell sizes that were too small to 
accurately represent adherence trends.  
 A few potential limitations that might impact inferences from the study are of 
note. There is the potential for non-differential misclassification of exposure due to the 
fact that although sex is patient reported, this sex may not be representative of the sex 
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used by the physician in medical decision making. This occurrence is unlikely, and the 
impact on our study would be minimal. Related to outcome, the original infection may 
have been misclassified due to the withholding of factors relevant to treatment by the 
patient or physician, which would not have been captured in the EMR, but this 
occurrence is unlikely given rigorous documentation processes required by the EMR. 
Therefore, the potential for any misclassification to alter measures of association is 
extremely small. There are few scenarios that would have permitted selection or 
information bias. Selection was not related to exposure or outcome and, although our 
evaluation is subject to the contents of the EMR, for reasons mentioned before, it is 
unlikely that patient sex resulted in differences in data collection or judgments regarding 
guideline adherence assignment. Despite a very short follow up time, there is also no 
concern for temporality, because sex could not have changed at any point during the very 
short duration between seeking and receipt of treatment. Confounders were widely 
assessed for this study, which supports prior history which did not account for any and 
provides information for future studies regarding relevant covariates.4,5 
This study was conducted in a setting that is accessible to a diverse population 
and investigated a disease for which all individuals are at risk. It is unclear how 
generalizable the results of this study are because mechanisms through which a sex-based 
differential occurred were unobserved or were not measured in this study.10,11 Because of 
lower risk associated with female patient sex, employment of gender stereotypes is 
unlikely. There was no significant interaction between patient and physician sex, thus 
effects of concordant or discordant pairing are also unlikely. Finally, we were unable to 
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evaluate mechanistic factors such as approachability because there was limited data on 
physician behavior in the charts. 
Physicians within one hospital often have similar practices as a result of being 
affiliated with the same association. There may be clustering by hospital type or by 
physician. Further research should gather physician-related data and adjust for clustering 
effects. It should also gather a wider variety of physician-related factors or include a 
larger sample size to allow for further detection of mechanisms or use a different setting.  
This research has implications for more tailored interventions aimed at reducing 
rates of treatment that does not adhere to guidelines by identifying which populations are 
affected by which adherence type. More widespread implementation of interventions 
aimed at reducing these disparities could increase guideline adherence and improve 
outcomes for patients. In some cases, guideline adherence may not directly correlate with 
improved care, especially when provisions of the guidelines conflict with each other and 
physicians must weigh multiple factors in making medical judgments. It is also possible 
that decisions made regarding the weighing of these factors is not indicated in the EMR, 
which would then not be visible to the researchers. Thus, care should be taken when 
equating adherence with beneficial care. This investigation also strengthens current 
literature that did not adjust for covariates by demonstrating that adjusting for covariates 
did not impact point estimates. Finally, these relationships warrant further research 
because no literature exists to our knowledge regarding the role of physician sex and 
cellulitis treatment or analysis of mechanisms directly impacting adherence for cellulitis 
treatment, thus there is limited prior knowledge to which we can compare these results. 
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Table 1. Number and Percent in Final Sample; Cellulitis Study, 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N (%)
Original Study Sample 1524 --
Excluded 164 10.8
     Incision & Drainage (Purulence) 36 2.4
     Repeat Visit 128 8.4
Final Study Sample 1360 89.2
Tabl ber and Percent in Final Sample; Cellulitis S udy, 2017.
 17 
Table 2. Distribution of Covariates According to Physician Treatment Guideline 
Adherence; Cellulitis Study, 2017. 
 
 
 
 
 
 
Table 2. Distribution of Covariates According to Physician Treatment Guideline Adherence; Cellulitis Study, 2017.
P-value
Patient Sex Male 84 11.46 316 43.11 333 45.43 0.01
N=1360 Female 68 10.85 320 51.04 239 38.12
CCI
N= 1360 Mild 131 11.05 578 48.74 477 40.22 0.0003
Moderate 20 14.93 45 33.58 69 51.49
Severe 1 2.5 13 32.5 26 65
Age
N=1360 <65 137 13.06 508 48.43 404 38.51 <0.0001
65+ 15 4.82 128 41.16 168 54.02
Age, Continuous 42.86 15.7 48.69 18.54 55.29 17.2 <0.0001
N=1360
Race/Ethnicity
N= 1345 White 110 10.82 445 43.76 462 45.43 <0.0001
Non-White 40 12.2 184 56.1 104 31.71
History of IVDU
N= 1360 No 98 8.09 598 49.38 515 42.53 <0.0001
Yes 54 36.24 38 25.5 57 38.26
Disposition
N=1360 Discharge 145 15.38 565 59.92 233 24.71 <0.0001
Admit 7 1.81 69 17.83 311 80.36
fisher: 
<0.0001 
CDU 0 0 2 6.67 28 93.33
Fever
N=1360 No 84 7.45 569 50.44 475 42.11 <0.0001
Yes 68 29.31 67 28.88 97 41.81
Location
N=1360 University 77 10.43 319 43.22 342 46.34 0.0023
Memorial 75 12.06 317 50.96 230 36.98
Physician Sex
N=1357 Male 97 11.66 413 49.64 322 38.7 0.0078
Female 55 10.48 222 42.29 248 47.24
Abbreviations: CCI - Charlson Comorbidity Index; CDU - Clinical Decision Unit; IVDU - Intravenous Drug Use
OvertreatedUndertreated
N (%)
Adherent
N(%)N(%)
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Table 3. Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for Patient 
Sex and Physician Treatment Guideline Adherence (Two-Level Outcome); Cellulitis 
Study, 2017. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 OR 95% CI OR 95% CI
Patient Sex
Male 1.00 Referent 1.00 Referent
Female 0.73 0.59-0.90 0.75 0.61-0.94
*Adjusted for CCI Score, Race, IVDU
Abbreviations: CCI - Charlson Comorbidity Index; IVDU - Intravenous Drug Use
Unadjusted Adjusted *    
Tabl adjusted and Adjusted Odds Ratios and 95% Confide ce 
Intervals for Pat e t Sex and Physician Treatment Guideline Adher nce 
(Two-Level Outcome); Cellulitis Study, 2017.
Guideline Non-Adherence
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Table 4. Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for Sex 
and Physician Treatment Guideline Adherence (Three-Level Outcome); Cellulitis Study, 
2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 POR 95% CI  POR 95% CI  POR 95% CI  POR 95% CI  POR 95% CI  POR 95% CI
Patient Sex
Male 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Female 0.80 0.56-1.14 0.71 0.57-0.89 0.89 0.61-1.29 0.72 0.57-0.91 0.89 0.61-1.29 0.72 0.57-0.92
Physician Sex
Male 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Female 1.06 0.73-1.53 1.43 1.14-1.81 1.03 0.70-1.53 1.48 1.16-1.88 1.03 0.70-1.53 1.47 1.16-1.87
p-interaction:   0.80
*Adjusted for age category, CCI score, race, IVDU
**Including physican sex and other covariates from prior model
Abbreviations: CCI - Charlson Comorbidity Index; IVDU - Intravenous Drug Use
Table 4. Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for Sex and Physician Treatment Guideline Adherence (Three-Level Outcome); Cellulitis Study, 2017.
Guideline Non-Adherence**
Undertreated Overtreated
Guideline Non-Adherence Guideline Non-Adherence*
Undertreated Overtreated Undertreated Overtreated
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Table 5. Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for Sex 
and Physician Treatment Guideline Adherence (Three-Level Outcome) Stratified by 
Intervention Status; Cellulitis Study, 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 POR 95% CI  POR 95% CI  POR 95% CI  POR 95% CI
Physician Sex
0.4
Pre-Intervention Female vs. Male 1.27 0.71-2.26 1.77 1.26-2.48 1.08 0.59-2.01 1.79 1.26-2.55
Post-Intervention Female vs. Male 0.93 0.57-1.49 1.24 0.89-1.72 1.00 0.60-1.67 1.28 0.91-1.79
Patient Sex
0.54
Pre-Intervention Female vs. Male 0.67 0.42-1.06 0.65 0.47-0.90 0.78 0.48-1.29 0.67 0.48-0.93
Post-Intervention Female vs. Male 1.02 0.59-1.78 0.82 0.59-1.13 1.09 0.61-1.94 0.77 0.55-1.08
*Adjusted for age category, CCI score, race, IVDU
Abbreviations: CCI - Charlson Comorbidity Index; IVDU - Intravenous Drug Use
Table 5. Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals for Sex and Physician Treatment Guideline Adherence (Three-Level 
Outcome) Stratified by In ervention Status; Celluli is Study, 2 17.
Guideline Non-Adherence Guideline Non-Adherence*
Undertreated Overtreated Undertreated Overtreated
p-value 
interaction
 21 
Figure 1. Percent of Patients Overtreated by Intervention Status; Cellulitis Study, 2017  
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